Member Info for bignose58

I wouldn't be surprised if we don't end the day flat or even in further negative territory.

The market is now def thinking the company is an even bigger joke than previously since they cannot follow their own as stated vision. Who would trust a bunch of people who do not even know what direction they want to go in. They state one thing and do exactly the opposite.

This has certainly become one big cluster F&%k.

9. No mention on the EU OTC progress. Only ref is made to the scaling up which, a they announced was done and dusted in 2017 !!!. It was stated in the YE results (which is after the 2nd March Op update) that they had already started the OTC roll-out in Jan !!! so why no mention of whether sales figure are positive or not or even that the launch has not taken place, Although there was a lot of time spent discussing the C-19 impact on Recordati, who I have already pointed out have made a profit and are paying a divi for 2020, there is no mention of the OTC rollout being delayed in the 2nd March update.

.....continued

5. Upscaling of the production line was performed years ago Dec 2017 (announcement related to EU launch) so why keep harping on about it and misleading investors now. It’s not like they need approval since in Jan they stated “This is designed, if successful, to meet Wanbang Pharmaceutical’s requirements for China and Recordati’s over-the-counter’s requirements in the European Union and the United Kingdom” Recordati already have the upscaling !!!.

6. NO explanation as to why the Chinese study requirement has nearly doubled in numbers (the FDA phase II was only 100 with phase III require even less - so I have been informed). It’s not even indicated whether this is down to the NMPA or if it is a requirement by Wanbang themselves. (why would the NMPA suddenly change to 285 when they had already agreed 150 ???). The CTA was awarded on the 5th Feb based on Wanbangs information announced on the 4th Jan. “The Company has been advised by Wanbang Pharmaceutical of the indicative summary details of the clinical study for seeking approval of an import licence for Senstend™ from the NMPA:” going on to say “an estimated enrolment of 150 men”. Yet in the 9th Feb announcement there is no mention of a change in numbers or extended start date.

If one uses the timeline of the FDA phase II which took 1 year to get just the first 30, how on earth does management think Wanbang are going to achieve 285 in the same time they stated it would take to get 150. There is just no logic there.

7. DLI. Apart from the statement "Deep Longevity is actively engaged with a number of leading life insurance companies and is exploring pilot engagements in both underwriting, customer acquisition and engagement". there is still no indication of any income from the investment. Are they effectively telling shareholders that DLI is still not making any money even to just cover operational costs (the DBC disaster comes to mind) ???

8. No further news on Japan. Is this now going down the same lines as the US license talks which stalled in 2014 at heads of terms (no reason given to shareholders why they walked) and as far as I am aware, although they are in contact with licensees, they had not even restarted license talks earlier in the year. How they can still make the statement that an agreement may be in place before the commencement of phase 3 is beyond me given they will have to re-thrash-out any agreements achieved in 2014.

Personally, I think it’s a carp announcement which is currently being reflected by todays SP and the current 3 to 1 sell/buy ratio.

1. Why on earth would they put Venturex as the first item??? It may be doing well, but given the company's strategy since 2015 as a Life Science investment vehicle is to offload legacy investments and move forward concentrating in the new and different sector, it is certainly sending the wrong message regarding the BOD/CEO/chairman's abilities as experienced business people to existing and prospective shareholders since they cannot keep to their trumpeted values and strategy.

2. That said. they now also intend to take up the offer of further investment in a legacy stock which is in total contrast to the company's vision "To be Hong Kong’s leading healthcare and life sciences investment enterprise. Its aim is to build a portfolio of late-stage healthcare and life sciences-related investments and commercialise them through ‘out-licensing’ to other strategic pharmaceutical partners". Surely if they are considering making further investments, they should be taking part in ANIC’s yesterdays announced placing? What on earth is the purpose of changing the company name to distance itself even further from the legacy investments at the end of the month if they continue to invest in legacy investments ?…. WTF. It certainly makes the paragraph within the YE results appear to be nothing less than complete and utter BS.…

“The Board considered that the change of name from Regent Pacific Group Limited to
Endurance RP Limited reflected the evolution of the Group’s business from the Company’s initial public offering in 1997 through to the present day. Since 2015, the Group had become increasingly focused on healthcare, life sciences and wellness, punctuated by the acquisitions of Plethora on 9 March 2016 and, more recently, DLI on 14 December 2020. Endurance RP Limited was, in the Board’s opinion, reflective of the Group’s current and anticipated investment focus and business, and the Board considered that it more accurately conveyed the current and future direction of the Group’s business, being in the healthcare, life sciences and wellness sectors. The new name would provide the Company with a more appropriate corporate image and identity which, the Board believed, would benefit the Company’s business development”

3. And yet still no ref to the ATO payment which Venturex was announced as being earmarked for. Still no explanation why the ATO allowed for the deferred 50% payment. Surely this in itself attracts interest payments. The ATO wouldn’t be doing their job properly if they were not charging any???

4 Amazing, but not unexpected, yet further delay of the Taiwan launch, which is now a couple of years after a license agreement had been made. It’s very easy to blame C-19 for the total incompetence for something that should be a relatively simple for a company like Orient..

Well that's interesting I write (s******) and it misinterprets the meaning..... next time ill just write lol.... !!!! WTF

Matador,

In that interview, he will probably ask if the piano in the background is a Fender Stratocaster (anyone seeing his last webinar will understand what I'm talking about)......s******.

The.Italian.

Jim Mellon's money fountains are actually upside-down money drains......lol

Another raid on the petty cash required... ;-)

I see a huge drop due to a discounted 40% on todays SP being quite a large dilution. I did wonder what made the SP rise 40% within several days (Actually between Apr 287h and May 5th). I suspect yet more"jiggery pokery"..... and Oh look who has a large holding in the company.....lol

Well, if previous schedules and timelines are anything to go by that have never been met, I won’t be holding my breath for May.

Just being realistic.

That shd have been is not classed :-)

Heimdal,

I’m sure The.Italian is classed a select person. All one has to do is email them. I’ve been updated several times b4 just by asking.

And Regents SP drops 4 to 5 %

Obviously traders do not care about an increase in value of a company and neither, it would appear, do the MM's who are currently buying the sold shares. It certainly doesn't appear to be attracting any new buyers that's for sure.

I wonder when this so called update is expected, it's certainly long overdue given Macau was launched weeks ago.

Morning Heimdal.

Let’s hope you are right and tight controls are in place since these things have a habit of spiralling out of control and not recognised till too late. Up 4% this am making up some of the drop yesterday.

Not wanting to throw too much water on the fire.

To start production, they will need a fair amount of investment which will come either through open market capital raises or by further investment from the partners. This ultimately will come at the price of dilution. I'm sure many will have witnessed. like myself, many companies that were run by people who in their previous projects turned million dollar companies into a billion dollar companies only to see them fail at the cost of shareholders. Just being realistic.

Hopefully Regent have the good sense to know when to call it a day and throw in the towel instead of being too greedy.

Heimdal,

Obviously your trade was split...according to the info shown here v

http://www.aastocks.com/en/stocks/analysis/transaction.aspx?symbol=00575

Afternoon Heimdal,

I think you may have your figures wrong. 17 buys (1.05mill) between about 09:50 and 10:50. VXR has pulled back to 0.695AUD. not sure what the 5c represents? Are you referring to 5c of the RPG sp currently at 0.198HKD ?

Although still low volume, lots of small buys this morning with not one sell in sight as I write. A leak of the pending update ???

Or just a coincidence ?

The.Italian,

For me it all depends on how much is invested. I guess selling the initial investment is always a good start and then just watch how the free capital works out. Anyway, as wrote good luck, it will be an interesting watch.

Agree, I think you are playing it right (lessons learnt with RPG). There will probably be a slow pull back until a license agreement is pulled out of the bag. I would think the quality of the first agreement will provide some indication of a licensees speculated sales and value (unlike Fortacin, ED sales are pretty well known and it will be based on how they feel this product will be accepted by users who would prefer a fast working gel as opposed to the usual pill...and OTC). If all goes well, you could see many multiples of even todays market cap.